

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.- 46. (canceled)

47. (presently amended) A method of inhibiting tumor growth in a mammal comprising administering to said mammal a dominant negative mutant of HAAH, wherein said HAAH comprises the amino acid sequence of SEQ ID NO:2 and wherein said mutant comprises a mutation, said mutation consisting of a substitution or deletion at residue 679 of SEQ ID NO:2.

48. (presently amended) A method of inhibiting tumor growth in a mammal comprising administering to said mammal a dominant negative mutant of HAAH, wherein said HAAH comprises the amino acid sequence of SEQ ID NO:2 and wherein said mutant comprises a mutation, said mutation consisting of a substitution or deletion at residue 690 of SEQ ID NO:2.

49. (previously amended) The method of claim 47 or 48, wherein said compound is administered directly into a tumor site.

50. (previously amended) The method of claim 47 or 48, wherein said compound is administered systemically.

51. (presently amended) The method of claim ~~16~~ 47 or 48, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.

52. (presently amended) The method of claim ~~16~~ 47 or 48, wherein said tumor is a cancer of the central nervous system.

53. (presently amended) The method of claim ~~16~~ 47 or 48, wherein said tumor is a hepatocellular carcinoma.

54. (presently amended) The method of claim ~~16~~ 47 or 48, wherein said tumor is a cholangiocarcinoma.

55. (presently amended) The method of claim ~~16~~ 47 or 48, wherein said tumor is a glioblastoma.

56. (presently amended) The method of claim ~~16~~ 47 or 48, wherein said tumor is a neuroblastoma.

57. (previously amended) A method of inhibiting growth of a tumor in a mammal comprising administering to said mammal an antibody selected from the group consisting of 5C7 produced by hybridoma ATCC designation PTA 3383, 19B produced by hybridoma ATCC designation 3384, and 86A produced by hybridoma ATCC designation 3385.

58. (new) The method of claim 57, wherein said antibody is 5C7.

59. (new) The method of claim 57, wherein said antibody is 19B.

60. (new) The method of claim 57, wherein said antibody is 86A.